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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine “Is platelet-rich
plasma injection effective for reducing pain & symptom severity in adults with carpal tunnel
syndrome?”
STUDY DESIGN: Systematic review of two randomized controlled trials and one nonrandomized controlled trial to analyze the overall effectiveness of platelet-rich plasma (PRP)
injections as a management for carpal tunnel syndrome (CTS). All three articles were published
in peer-reviewed journals after the year 2016.
DATA SOURCES: These two RCTs and one non-RCT were found using Pubmed and were
selected based on their year of publication, population of individuals with mild to moderate CTS,
relevance to clinical question, and ability to meet POEM criteria.
OUTCOMES MEASURED: Patients in these three studies reported pain level measured by the
Visual Analog Scale (VAS) and symptom severity measured by the Symptom Severity Scale
(SSS)
RESULTS: Raeissadat et al. reported that PRP is not an effective treatment for CTS since there
was no statistically significant evidence to support that at 10 weeks, PRP injections with a wrist
splint added any benefit in VAS and SSS scoring compared to splinting alone (BMC
Musculoskelet Disord. 2018;19(1). doi:10.1186/s12891-018-1963-4.). Wu et al. concluded that
PRP is an effective treatment for CTS if used for 6 months. However, applying an endpoint of 3
months to make the study directly comparable to the others shows that a 3 month treatment
period was not long enough to demonstrate statistically significant benefit of using PRP on the
VAS, despite yielding statistically significant positive results on the SSS in month 3 (Sci Rep.
2017;7(1). doi:10.1038/s41598-017-00224-6.). In contrast, Atwa et al. showed that at the 1 and 3
month follow-ups, PRP injections were sometimes significantly better in relieving pain and
symptom severity than corticosteroid injections since the PRP group overall scored lower on the
VAS and SSS with p values <0.05 at both times, however the standard deviation was high
enough to cause concern in the validity of these results. (The Egypt Rheum. 2018.
doi:10.1016/j.ejr.2018.07.008.).
CONCLUSIONS: Based on the three studies analyzed, it can be concluded that PRP injection is
not an effective treatment for reducing pain and symptom severity in adults with CTS.
KEY WORDS: platelet-rich plasma, carpal tunnel syndrome
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INTRODUCTION
Carpal tunnel syndrome (CTS) is a type of peripheral entrapment neuropathy associated
with etiologies such as repetitive overuse of the wrist. Other causes may include trauma,
pregnancy, and specific disease pathophysiology like diabetes mellitus, sarcoidosis, amyloidosis,
obesity, arthritis and hypothyroidism. Regardless of the specific cause, symptoms such as pain,
numbness, tingling, and loss of muscle strength in the median nerve innervation arise from
compression of the median nerve in the carpal tunnel under the transverse carpal ligament.
Patients complain of an irritating and even painful sensation that radiates down their forearm into
components of their hand, making the fingers feel weighted and unusable. Symptoms may also
spread upwards towards the arm and shoulder of the affected limb. Regardless of the location of
pain, patients typically see no erythema or edema.1
CTS makes up 90% of peripheral nerve entrapment cases,2 and without intervention, CTS
can significantly limit daily activities, hindering individuals’ overall quality of life and ability to
function.3 In 2011, it was estimated that 2.7-5.8% of the general population had carpal tunnel
syndrome, and the average annual incidence was 329 per 100,000 person-years.1
Each year in the US, CTS accounts for a total cost of $2 billion in medical costs. Mostly
due to the surgical procedures required to relieve symptoms of this condition, carpal tunnel
syndrome can be considered the most expensive upper extremity musculoskeletal disorder in the
United States.4 Not only does this condition cost actual dollars, but it can take away from time in
the workplace, ultimately leaving most individuals with a lower income, and some, without a
job. In fact, the average annual time missed from work due to carpal tunnel-related
disability is 27 days. Surprisingly, this data only comes second to fractures in missed workdays.4
Additionally, it has been noted that within 18 months of beginning a job, when an individual
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worker develops CTS, there is an 18% chance they will inherently leave that job due to it.4 CTS
is undoubtedly a detrimental disorder to the United States population financially, functionally,
and emotionally.
It is not known how many yearly healthcare visits occur from CTS, but it is known that
CTS is more common in the working populations at an incidence of 5-21%,4 mostly seen in
occupations where repetitive wrist motions are necessary. Examples of such occupations include
food processing, the logging industry, and carpentry. This is compared to a lower incidence in
the general population at 1-5%.4
It is known that CTS is due to the physical compression of the median nerve in the
transverse carpal ligament of the wrist. Typically, there is a traceable pattern of symptoms over
the patient’s hand and forearm that follow the median nerve innervation which helps guide the
diagnosis of CTS using physical exam techniques such as Tinel sign, Phalen maneuver, or a flick
sign. However, 9% of patients can have a symptomatic presentation that is unusual for the
diagnosis which can prolong the diagnostic period or require additional tests.1 If not treated
properly, CTS can lead to permanent nerve damage of the affected regions.1
There are measures for CTS treatment that are typically used as a first-line treatment
before decompression surgery. These modalities include wrist splints, NSAIDs, corticosteroid
injections, and physical therapy. Unfortunately, it was reported that close to 60-70% of
individuals undergoing these conventional management techniques remain symptomatic after 18
months.4 Surgical decompression is certainly more effective than the alternative methods
mentioned, but it has a large range of failure rates at 7-75%.5 It is only truly suggested for
patients with severe CTS or for patients with symptoms that are highly resistance to the
previously mentioned measures of management.5 Due to the substantial disability this condition

Latimer, PRP treatment for carpal tunnel syndrome 3
holds, research into effective treatment regimens is most certainly warranted. The newest
research being conducted is on the use of platelet-rich-plasma (PRP) injections as an alternative
to the current mainstays of treatment. PRP is a mixture dense in platelets and growth factors that
has been previously used for wound healing and angiogenesis in the fields of neurosurgery,
dentistry, and cosmetics, and there is strong evidence for its effectiveness in axon regeneration
and repair of neurons. Using this knowledge as a basis for its therapeutic use, PRP could possibly
become a treatment option for patients to relieve CTS symptoms, prolonging their need for
decompression surgery or even preventing it altogether. This review uses 2 RCTs and 1 nonRCTs to analyze the overall effectiveness of PRP injections as a management for the symptoms
of CTS.
OBJECTIVE
The objective of this selective EBM review is to determine “Is platelet rich plasma
injection effective for reducing pain & symptom severity in adults with carpal tunnel
syndrome?”
METHODS
All research and interpretation for this review including specific article selection were
completed by the author. Three studies published in the English language were analyzed in this
systematic review and were found using Pubmed and the keywords Platelet-rich Plasma and
Carpal Tunnel Syndrome. Articles were selected based on their relevance to the clinical question,
year of publication after 2016, population of individuals with mild-moderate CTS, and ability to
meet POEM criteria. Exclusion criteria for this study included disease-oriented evidence,
population under 20-years-old and above 60-years-old, articles written in a language other than
English, and previously published Cochrane systematic reviews. Two of these studies were
randomized control trials, while one was a non-randomized control trial, but they all analyzed
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whether PRP is an effective treatment for mild to moderate CTS. The outcome measures used
and analyzed in all three of these trials were the Visual Analogue Scale (VAS) and the Symptom
Severity Scale (SSS) of the Boston Carpal Tunnel Questionnaire (BCTQ).2, 3, 5 The intervention
used in these trials was platelet rich plasma injections (PRP) into the median nerve and PRP
combined with splinting, and it was compared to the interventions of corticosteroid injections
into the median nerve as well as wrist splinting alone.2, 3, 5 The statistics of this study were found
using p-values, standard deviation and mean change from baseline. The patient demographics
and criteria met for each article are described in Table 1.
Table 1. Demographics & Characteristics of included studies

Study

Type

#
Age
of (yrs)
Pts

Inclusion
Criteria

Exclusion Criteria

W/D

Interv
ention
s

Raeissa
dat2
(2018)

RCT

41

Betwe
en 2060 yo

Women at physical
medicine/rehab
clinics at Shahid
Modarres Hospital
(2016) with mildmod CTS signs and
sx and confirmed
diagnosis based on
H&P, + Phalen’s
test and
electrophysiology

b/l CTS, pregnancy, hx of met
d/s, corticosteroid use in last 3
months, thenar atrophy,
previous CTS release,
neuropathy/ radiculopathy
evidence, PRP CIs (malignancy
history, autoimmune or
hematological disorders,
NSAID consumption in last 2
days, anti-platelet/anticoagulation use, Hb levels
<12g/dL, PLT <150,000/mL)

0

PRP
injectio
n
combine
d with
night
splint
VS.
night
splint
alone

Atwa3
(2018)

Non
RCT

36

Betwe
en 2050
years
old

Idiopathic mild-mod
CTS being treated
for 1 month w/o
improvement

TCP, local infection, NSAID
use, 2ndary CTS, past hx of
corticosteroid injection into
same wrist or severe CTS

0

PRP
VS.
corticost
eroid
injectio
ns

Wu5
(2017)

RCT

60

Betwe
en 2050
years
old

Mild-mod unilateral
CTS w/ clinical sx
for 3 mo undergoing
electrophysiology
and ultrasound

History of wrist surgery,
polyneuropathy, brachial
plexopathy, thoracic outlet
syndrome, hx of TCP, systemic
infection, pregnancy,
rheumatological disorders,
previous steroid injection

0

PRP
injectio
ns VS.
night
splint
use
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OUTCOMES MEASURED
The outcomes measured in this study included pain level change using the Visual
Analogue Scale (VAS) and change in severity of symptoms using the Symptom Severity Scale
(SSS). Data was collected through both of these measurement scales by subjects self-reporting
pain and symptom severity. The VAS is a tool for patients to rate their pain on a scale of 0 (no
pain) to 10 (worst pain) using pictures for reference. The SSS is a component of the BCTQ
where patients rate their severity of CTS symptoms using an 11-question questionnaire with each
question scaled 1 (least severe) to 5 (most severe), making a total possibility of 55 points to
gauge severity of symptoms. Raeissadat et al.2 measured these two outcomes at 10 weeks, Wu et
al.5 at 1, 3 and 6 months, and Atwa et al.3 at 1 and 3 months to determine the efficacy of PRP
injections for CTS. The endpoint of this review is set at 3 months.
RESULTS
This review uses three different studies to compare multiple forms of therapy for CTS
with the intention to explain whether PRP injection is an effective treatment for CTS. All three
studies include adults between the ages of 20 and 60 years old. Keeping in mind that the
Raeissadat et al.2 study concluded at 10 weeks, and the Wu et al.5 and Atwa et al.3 studies
collected data at 3 months, the end point of this study is set at 3 months, noting this two-week
discrepancy.
The study by Raeissadat et al.2 is a randomized trial conducted at Shahid Beheshti
University of Medical Sciences to show the safety and efficacy of PRP injections in the
treatment of CTS. It used 41 women, placing 20 in the control group and 21 in the treatment
group. All 41 subjects completed the trial. An overnight prefabricated wrist splint at 5 degree
extension was used on the control group for 8 weeks.2 The treatment group was treated with the
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same splinting regimen but also with a median nerve injection of 1mL of autologous PRP. The
mean change in each group of variables of VAS and SSS were recorded after 10 weeks.2
Inclusion and exclusion criteria for this study can be found in Table 1. Although there was a
mean decrease in both treatment and control groups of pain and symptom severity, the data
displayed in Table 2 does not support the benefit of using PRP in addition to splinting as a
treatment option for CTS.2 Ultimately, with standard deviations calculated very close to the
means and with p values considerably larger than 0.05, there is no statistically significant
evidence to support the claim that PRP is effective for CTS treatment.2
Table 2. Pain & symptom severity reduction at 10 weeks by Raeissadat et al.
Variables

Group

Mean

SD

VAS change 10 wks

Control (n = 20)

-2.90

2.1

Treatment (n = 21)

-2.76

2.4

Control (n = 20)

-0.70

0.3

Treatment (n = 21)

-0.72

0.7

P value (adjusted for age)

0.398

SSS change 10 wks

0.629

The study conducted by Wu et al.5 is a single-blind randomized trial that used 60
participants, 30 in the treatment and 30 in the control group to determine the six-month efficacy
of PRP for CTS. All 60 participants completed the study. The research was conducted at the TriService General Hospital, National Defense Medical Center in Taiwan, Republic of China. A
total of 3mL of autologous ultrasound-guided PRP injection was used in subjects in the treatment
group while subjects in the control group wore a wrist splint alone in the neutral position for at
least 8 hours a day during the time of the study.5 Inclusion and exclusion criteria for this study
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can be found in Table 1. The mean change of the variables VAS and SSS was measured at 1
month, 3 months, and 6 months. Due to the limited time frames in the Raeissadat et al.2 and
Atwa et al.3 studies at 10 weeks and 3 months respectively, the data in this study collected at
month 6 will not be considered in this review with an endpoint of 3 months. It was seen that both
groups in this study displayed a reduction in both pain and symptom severity at 1, and 3 months,
however, only the SSS data at month 3 can be used as supporting evidence towards PRP
injections effectiveness in CTS due to it being the only data within the 3 month endpoint with a p
value <0.05 and standard reasonably low deviation.5
Table 3. 1, 3, and 6 month change in pain and symptom severity in corticosteroid vs PRP
group as measured by VAS and SSS by Wu et al.
PRP Group (n = 30)

Control Group (n = 30)

Mean Difference + SF

Mean Difference + SF

VAS-Pre

(6.50 + 0.30)

(6.29 + 0.31)

VAS month 1

-2.61 + 0.26

-2.41 + 0.20

0.540

VAS month 3

-3.59 + 0.34

-2.93 + 0.20

0.104

VAS month 6

-4.53 + 0.37

-3.30 + 0.34

0.018

SSS-Pre

(26.17 + 1.10)

(24.93 + 1.22)

SSS month 1

-8.93 + 1.10

-6.50 + 0.94

0.098

SSS month 3

-10.47 + 1.17

-6.80 + 0.93

0.017

SSS month 6

-11.76 + 1.21

-8.73 + 0.85

0.045

p value

The study by Atwa et al.3 was conducted to study PRP versus corticosteroid injections for
treatment of CTS symptoms. It used 36 patients who all completed the trial, 18 patients in the
control group receiving a single injection of the corticosteroid methylprednisolone 40mg/1.0mL
and 18 patients in the treatment group receiving PRP injections of 2mL into the median nerve
with 24 hours of rest following PRP injections.3 Subjects were recruited from the Rheumatology
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and Rehabilitation outpatient clinic, Zagazig University Hospitals. Table 1 outlines the inclusion
and exclusion criteria of the study. The mean change of VAS and SSS were measured at 1 and 3
month periods.3 The results showed with great confidence represented by the p intervals <0.05
that there was a significant total decrease in pain and symptom severity from baseline in both the
treatment and control groups at 1 and 3 months although there was a slight increase in pain and
symptom severity from 1 to 3 months in both groups. However, it can be said that the most
significant decrease in pain and symptom severity at both 1 and 3 months from baseline was
found in the group treated with PRP. On the other hand, despite the low p values, the large
standard deviations on the mean values are a cause for concern. By definition of standard
deviation, 99.7% of the data lies within 3 standard deviations of the mean in a normal
distribution. This suggests that there may have been data points very far from the mean, which
contradicts the notion that PRP was an effective treatment as a whole. Therefore, this study is not
entirely supportive of the effectiveness of PRP to treat CTS.
Table 4. 1 and 3 month change in pain and symptom severity in CS vs PRP injections as
measured by VAS and SSS by Atwa et al.
Parameter mean + SD

VAS

SSS

Group I Corticosteroid (n =
18)

Group II PRP (n = 18)

p value

Baseline

7.2 + 1.3

7.05 + 1.4

0.8

1 month

3.5 + 2.35

2.1 + 2.6

0.03

3 months

5.2 + 1.9

3.4 + 2.09

0.002

p value

0.0001

0.0001

Baseline

36.8 + 7

33.2 + 6

0.1
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1 month

22.3 + 7.4

18.6 + 10.7

0.02

3 months

28.6 + 6.8

21.5 + 10.2

0.001

DISCUSSION
Although treatments such as corticosteroid injections, wrist splinting, and NSAIDs exist,
they unfortunately have little to no permanent effect for patients who severely suffer from
symptoms of this syndrome. Patients are left with the option of invasive decompression surgery
that commonly brings its own risks such as adjacent vessel damage, sensitive scarring and
infection.5 This selective evidence-based medicine review focused on the specific use of PRP
injections as a treatment option for CTS and studied its use for pain and symptom severity in a 3
month time frame. PRP injections have been used to promote healing for alternative means such
as orthopedic, dental and plastic surgery procedures since the late 1980s.6 This review does not
support much promise towards the use of PRP injections for CTS treatment. The Atwa et al.
study when compared to standard treatments of splinting and corticosteroid injection use would
have been very supportive if it were not for the large standard deviations.3 The studies conducted
by Raeissadat et al. and Wu et al. did not strongly and statistically show support for the
effectiveness of PRP for CTS treatment either outside of the Wu et al. study’s SSS results at 3
months.2, 5
It should be noted that none of the three studies analyzed were conducted in the United
States nor were US studies on this topic found; therefore, the use of PRP injections in individuals
outside of the United States may play a factor in this treatment option’s efficacy in these trials.
Although the use of activated PRP injections are not approved by the FDA and must be used
“off-label” in the US, and there is no evidence to support its availability for use in the US, it is
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being explored in other countries for the use described in this study. It should also be noted that
PRP use for other therapies has been deemed safe when mixed with other substances, but it has
seen its drawbacks such as for its use in musculoskeletal pain where side effects of local
infection and pain at the site of the injection can be seen.6
Limitations to these studies are evident and may have played a role in the final outcome
of the studies. Concerning the article by Raeissadat et al.,2 in both the control and treatment
group, data on the patient population was halted at 10 weeks. Conversely, the Atwa et al.3 and
Wu et al.5 studies were conducted to 1 and 3 months and 1, 3 and 6 months respectively.
Although these were indeed short follow-up times, these inconsistent time frames made it
difficult to choose an endpoint for this review. With the final endpoint chosen at 3 months, there
is an obvious two-week discrepancy between the Wu et al.5 and Atwa et al.3 studies when
compared to Raeissadat et al.,2 leaving room for a potential change in outcome if the Raeissadat
et al.2 study had been conducted two weeks longer. The longer studies also could have benefitted
by questioning subjects at monthly intervals instead of at multiple month intervals. Other
limitations include small sample sizes, lack of double-blinding in all three studies and lack of
randomization in the Atwa et al. study.3 In order to make an even stronger statement concerning
the value of PRP injection for CTS treatment, these limitations must be addressed in future
studies.
CONCLUSIONS
After analyzing these three studies for the purpose of this review, it can be concluded that
PRP is not an effective treatment for CTS. The most support for this conclusion is found in the
Wu et al. study which showed PRP benefit throughout the entire six-month study when
compared to night splinting, but the data was provided with p values >0.05 at SSS month 1, and
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VAS month 1 and 3, making the data at these time frames statistically insignificant. However,
PRP injections showed benefit in regard to SSS at 3 and 6 months and VAS at 6 months with p
values <0.05, but due to this review’s endpoint being 3 months, it can only be stated that Wu et
al. shows support for PPR injections for treatment of CTS’s SSS at 3 months. The study by
Raeissadat et al.2 did not provide sufficient statistical evidence to support the claim that PRP
adds any benefit to patient’s CTS symptoms. Although both treatment and control groups
displayed a decrease in pain and symptom severity at 10 weeks, the p values were >0.05 and
standard deviations were large, making the data statistically insignificant. The final study by
Atwa et al.3 also supported the same conclusion. Although there was a significant decrease in
pain and symptom severity in both the PRP and control group with p values <0.05 at both 1 and
3 months, PRP did display the greatest decrease in pain and symptom severity, showing some
support for PRP effectiveness in CTS treatment. However, due to large standard deviations in the
mean values recorded, there is ample room to doubt the effectiveness of the use of PRP in the
treatment of CTS. Future studies would warrant larger sample sizes in order to achieve more
conclusive data. Research would also benefit by selecting a study endpoint as well as a dose of
PRP that is similar to previously conducted studies for the ease of comparative data.
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